(Yicai Global) June 9 -- China’s WuXi Biologics, which runs open-access technology platforms for drug development, has signed a 10 year lease for a clinical manufacturing facility in the United States, its third in the country.

The new 6,131 square meter plant in Cranbury, New Jersey, will have 6,000 liter bioreactors and labs for process development and quality control, the company said in a statement today. It hopes to open the facility this year.

WuXi Biologics already has two such facilities in the US, one in Worcester, Massachusetts, and another in King of Prussia, Pennsylvania.

Shares in the firm [HKG:2269] were up 1.28 percent at HKD126.60 (USD16.33) as of 10.13 a.m.

Editor: James Boynton